The viscosupplementation market is witnessing significant growth due to rising demand for minimally invasive treatment options for osteoarthritis. Viscosupplements offer pain relief, joint lubrication, and improved mobility, enhancing the quality of life for patients. Advancements in product formulations and delivery methods are further driving market expansion. The aging population and increasing awareness of viscosupplementation's benefits contribute to its positive outlook. The market's growth potential presents lucrative opportunities for manufacturers to develop innovative products and meet the growing demand for effective osteoarthritis management solutions.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-viscosupplementation-market
Data Bridge Market Research analyses that the Global Viscosupplementation Market is expected to grow to a USD 3,730.56 Million by 2029 from USD 1,952.54 Million in 2021, growing at a lucrative CAGR of 8.5% in the forecast period of 2022 to 2029. Continued product launches and introduction of novel viscosupplements offer patients a wider range of treatment options. This enhances the market's global reach, making advanced viscosupplements more accessible to patients, leading to increased adoption and market expansion.
Key Findings of the Study
Favorable reimbursement policies is expected to drive the market's growth rate
Favorable reimbursement policies in certain regions provide financial support and coverage for viscosupplementation procedures, making them more accessible and affordable for patients. Improved reimbursement encourages healthcare providers to offer viscosupplementation treatments, leading to increased utilization and adoption of this non-surgical therapy for osteoarthritis. This positive impact on patient affordability and the willingness of healthcare providers to offer the treatment support the market's growth by expanding the use of viscosupplements in various healthcare settings.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Source (Animal Origin And Non-Animal Origin), Age Group (Geriatric And Adults), Injection (Single Injection, Three Injections, And Five Injections), Molecular Weight (Intermediate Molecular Weight, Low Molecular Weight And High Molecular Weight), End User (Hospital, Orthopedic Clinics, Ambulatory Care Centers, And Others), Distribution Channel (Direct Tender And Retail Sales)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Anika Therapeutics, Inc. (U.S.), SEIKAGAKU CORPORATION (Japan),Bioventus (U.S.),Fidia Farmaceutici S.P.A (Italy), Ferring B.V (Switzerland), sanofi-aventis U.S. LLC (U.S.),Zimmer Biomet (U.S.), OrthogenRx, Inc. (a subsidiary of AVNS) (U.S.), APTISSEN (France), Johnson & Johnson Services, Inc. (U.S.), LG Chem. (South Korea), Viatris Inc. (U.S.), IBSA Institut Biochimique SA (Switzerland), Ortobrand International (U.S.), TRB CHEMEDICA SA (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Lifecore (a subsidiary of Landec Corporation) (U.S.), VIRCHOW BIOTECH (India), Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals) (India) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The viscosupplementation market is segmented on the basis of source, age group, molecular weight, injection, end user, and distribution channel
- On the basis of source, the global viscosupplementation market is segmented into the animal origin and non-animal origin. Non-animal origin segment is expected to dominate the source segment of the global viscosupplementation market with a CAGR of 8.7% in the forecast year of 2022 to 2029 due to commonly used in medical and pharmaceutical industries, providing essential components for various products, research, and therapeutic applications.
In 2022, the non-animal origin segment is expected to dominate the source segment of the global viscosupplementation market
In 2022, Non-animal origin segment is expected to dominate the source segment of the global viscosupplementation market owing to commonly used in the pharmaceutical and medical industries, providing vital ingredients for a range of goods, studies, and therapeutic uses with a CAGR of 8.7% in the forecast year of 2022 to 2029.
- On the basis of molecular weight, the global viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight. Intermediate molecular weight segment is expected to dominate the modular weight of the global viscosupplementation market with a CAGR of 9.1% in the forecast period of 2022 to 2029 due to their versatility in various applications, striking a balance between high and low molecular weight compounds. They find wide use in pharmaceuticals, polymers, and research, offering desirable properties for specific purposes.
- On the basis of injection, the global viscosupplementation market is segmented into single injection, three injections, and five injections. Single injection segment is expected to dominate the injection segment of the global viscosupplementation market with a CAGR of 9.1% in the forecast period of 2022 to 2029 due to its convenience and simplicity. It offers a one-time treatment option, reducing the need for multiple visits and enhancing patient compliance, making it a preferred choice for viscosupplementation procedures.
In 2022, the single injection segment is expected to dominate the injection segment of the global viscosupplementation market
In 2022, the single injection segment is expected to dominate the injection segment of the global viscosupplementation market owing to its simplicity and convenience. It is a preferred option for viscosupplementation procedures because it provides a one-time treatment option, obviates the need for repeated visits, and improves patient compliance with a CAGR of 9.1% in the forecast period of 2022 to 2029.
- On the basis of age group, the global viscosupplementation market is segmented into geriatric and adults. Geriatric segment is expected to dominate the global viscosupplementation market with a market share of 71.74% in the forecast period of 2022 to 2029 due to higher susceptibility to osteoarthritis and joint-related issues. As the elderly population grows, the demand for viscosupplementation treatments increases, making it a significant market segment in managing joint pain and improving mobility for this age group
- On the basis of end-user, the global viscosupplementation market is segmented into hospital, orthopedic clinics, ambulatory care centers, and others. Hospitals segment is expected to dominate the global viscosupplementation market with a CAGR of 9.3% in the forecast period of 2022 to 2029 due to their comprehensive healthcare services and facilities. Viscosupplementation treatments often require specialized medical expertise and equipment, making hospitals the ideal setting for delivering these procedures to patients effectively and safely.
- On the basis of distribution channel, the global viscosupplementation market is segmented into direct tender and retail sales. Retail sales segment is expected to dominate the global viscosupplementation market with a CAGR of 8.8% in the forecast year of 2022 to 2029 due to direct consumer interaction, offering convenience and immediate access to viscosupplements. Patients can purchase these products directly from retail outlets, pharmacies, or online platforms, ensuring easy availability.
Major Players
Data Bridge Market Research recognizes the following companies as the major viscosupplementation market players in viscosupplementation market are LG Chem. (South Korea), Viatris Inc. (U.S.), IBSA Institut Biochimique SA (Switzerland), Ortobrand International (U.S.), TRB CHEMEDICA SA (Switzerland)
Market Developments
- In 2022, Juniper Biologics signed a licensing deal with Kolon Life Sciences to develop and commercialize, TissueGene-C low dose (TG-C LD), non-surgical investigational therapy administered as a single intra-articular injection, to treat knee osteoarthritis.
- In June 2022, Johnson & Johnson announced new data from Phase 3 studies demonstrating patients treated with medicine achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis, a dactylitis,b spinal pain, and disease severityc endpoints – irrespective of baseline characteristics.
- In 2021, Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation launched JOYCLU 30mg intra-articular injection, a joint function improvement agent, for which Seikagaku received the manufacturing and marketing approval, in Japan, in March 2021.
- In 2020, Viatris Inc. launched a successful combination of Mylan N.V. and Pfizer's Upjohn business. Combining these two complementary legacy companies, Viatris has the scientific, manufacturing, and distribution expertise with proven regulatory, medical and global commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. This has helped company to expand its business
Regional Analysis
Geographically, the countries covered in the viscosupplementation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in global viscosupplementation market during the forecast period 2022 to 2029
North America's dominance in the viscosupplementation market is attributed to the presence of major market players and its largest consumer base with a high GDP. The U.S. is expected to witness growth due to advancements in drug treatments, especially in viscosupplements used to alleviate joint pain and osteoarthritis. The region's emphasis on technological advancements, coupled with a rising aging population, drives the demand for effective and innovative viscosupplementation therapies, fostering market expansion and development.
For more detailed information about the viscosupplementation market report, click here – https://www.databridgemarketresearch.com/reports/global-viscosupplementation-market
